Arterys Cardio DL vs Autoplaque
AI Verdict
Choose Arterys Cardio DL if…
Choose Arterys Cardio DL if your institution primarily utilizes cardiac MRI for comprehensive cardiac function assessment and requires rapid, automated ventricle segmentations to significantly reduce interpretation time. This cloud-based solution is ideal for enhancing diagnostic accuracy and performing advanced analyses like 4D Flow post-processing and quantitative Delayed Enhancement.
View Arterys Cardio DL →Choose Autoplaque if…
Choose Autoplaque if your clinical focus involves detailed quantitative analysis of coronary plaques and luminal stenoses from CT angiography images for heart attack risk prediction and treatment guidance. This workstation-based software is best suited for clinicians needing precise, automated segmentation and characterization of atherosclerotic plaque to inform cardiovascular management strategies.
View Autoplaque →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Arterys Cardio DL | Autoplaque |
|---|---|---|
| Deployment | Cloud-based (SaaS), integrates with existing PACS or EHR, web-based zero-footprint viewer (Mac, PC, tablet, phone). [4, 7, 9, 13, 27] | Workstation-based post-processing application, runs on Windows or Mac OS. |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Arterys Cardio DLArterys Cardio DL is a cloud-based platform, offering superior accessibility and scalability, and significantly reduces cardiac MRI interpretation time from minutes to seconds. This enhances workflow efficiency and user experience, making it more adaptable to various clinical environments. Autoplaque, being workstation-based, may have more traditional deployment challenges.
Clinical Value
AutoplaqueWhile both tools are FDA-cleared and offer significant clinical benefits, Autoplaque directly aids in heart attack risk prediction and treatment guidance through quantitative analysis of coronary plaques and stenoses from CT angiography. Clinical validation studies highlight its prognostic value for future cardiac events and its ability to significantly improve cardiovascular risk prediction.
Pricing & Value
TieBoth tools lack transparent pricing information, making it impossible to conduct a head-to-head comparison of their cost-effectiveness or overall value. Without disclosed pricing, potential customers cannot easily assess the financial implications of adopting either solution.
Enterprise Readiness
Arterys Cardio DLArterys Cardio DL is cloud-based, explicitly states HIPAA compliance and BAA availability, and is vendor-agnostic, making it highly suitable for large-scale enterprise deployment. Its global clearance in nearly 100 countries further demonstrates its readiness for broad adoption. Tool B's workstation-based deployment and unspecified BAA/HIPAA status present potential hurdles for enterprise integration.
Innovation
Arterys Cardio DLArterys Cardio DL is a foundational innovator, recognized as the 'world's first internet platform for medical imaging' and the 'first technology to be cleared by the FDA that leverages cloud computing and deep learning in a clinical setting'. This represents a broader, more architectural innovation in the delivery and application of AI in medical imaging.
Support & Docs
TieNeither the provided structured facts nor the web searches yielded substantial information regarding the availability of comprehensive support channels or detailed documentation for either tool. While Autoplaque's FDA document implies a user manual, there isn't enough information to definitively declare a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Arterys Cardio DL | Autoplaque |
|---|---|---|
| Name | Arterys Cardio DL | Autoplaque |
| Company | ARTERYS | Cedars-Sinai Medical Center: AIM |
| Description | FDA-cleared, cloud-based AI software that provides automated, editable ventricle segmentations for cardiac MRI analysis, drastically reducing interpretation time and enhancing diagnostic accuracy. | FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. |
| Key Features | Automated ventricle segmentations for cardiac MRI; Deep learning algorithms for image analysis; Cloud-based platform for accessibility and performance; Vendor-agnostic compatibility; Rapid analysis (seconds vs. 30-60 minutes); Editable automated contours; 4D Flow post-processing for blood flow visualization and quantification; Quantitative Delayed Enhancement analysis | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images; Workstation-based post-processing application; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views; Measurement of vessel diameter and area |
| Specialties | Cardiology, Radiology | Cardiology, Radiology |
| Imaging Modality | Cardiac MRI | CT Angiography (CTA) |
Videos
Demos, reviews, and walkthroughs featuring Arterys Cardio DL and Autoplaque.